Berliner Boersenzeitung - Ketamine pill treats depression without psychedelic effects: study

EUR -
AED 4.236411
AFN 76.134675
ALL 93.182464
AMD 422.487247
AOA 1058.957992
ARS 1726.291717
AUD 1.638296
AWG 2.079272
AZN 1.957663
BAM 1.954392
BBD 2.322816
BDT 142.757152
BHD 0.434883
BIF 3446.886847
BMD 1.153549
BND 1.478828
BOB 13.949011
BRL 5.892788
BSD 1.153264
BTN 109.754928
BWP 15.597695
BYN 3.414525
BYR 22609.559189
BZD 2.319419
CAD 1.617766
CDF 2608.174036
CHF 0.93494
CLF 0.026655
CLP 1052.440081
CNY 7.786316
CNH 7.784327
COP 3650.590183
CRC 524.590231
CUC 1.153549
CUP 30.569047
CVE 110.185618
CZK 24.233468
DJF 205.370263
DKK 7.47577
DOP 67.201294
DZD 153.450895
EGP 57.316497
ERN 17.303234
ETB 186.142082
FJD 2.552746
FKP 0.856878
GBP 0.856735
GEL 3.016492
GGP 0.856878
GHS 13.556292
GIP 0.856878
GMD 84.787876
GNF 10128.702886
GTQ 8.79966
GYD 241.274085
HKD 9.049096
HNL 30.910597
HRK 7.53544
HTG 150.790711
HUF 364.519161
IDR 20647.372445
ILS 3.46953
IMP 0.856878
INR 109.834412
IQD 1510.805008
IRR 1585899.080318
ISK 142.416699
JEP 0.856878
JMD 182.808298
JOD 0.817933
JPY 182.556612
KES 149.22293
KGS 100.877923
KHR 4679.608344
KMF 492.565076
KRW 1640.91172
KWD 0.357128
KYD 0.961103
KZT 540.432993
LAK 26058.000902
LBP 103275.743756
LKR 387.390908
LRD 208.169125
LSL 18.810948
LTL 3.40613
LVL 0.69777
LYD 7.351704
MAD 10.760248
MDL 20.066456
MGA 4958.406278
MKD 61.485437
MMK 2421.811214
MNT 4147.977671
MOP 9.318746
MRU 46.234691
MUR 54.148043
MVR 17.822046
MWK 1999.741972
MXN 19.840834
MYR 4.717788
MZN 73.723223
NAD 18.810866
NGN 1571.940531
NIO 42.439425
NOK 11.010746
NPR 175.605964
NZD 1.962366
OMR 0.443552
PAB 1.153259
PEN 3.898292
PGK 5.095329
PHP 70.036572
PKR 320.176332
PLN 4.298908
PYG 6860.028033
QAR 4.215763
RON 5.25556
RSD 117.322806
RUB 94.045967
RWF 1694.172109
SAR 4.331728
SBD 9.307235
SCR 16.719259
SDG 692.70723
SEK 10.951378
SGD 1.479877
SLE 28.385109
SOS 659.122286
SRD 43.680858
STD 23876.134015
STN 24.482256
SVC 10.09073
SZL 18.795296
THB 38.153561
TJS 10.638843
TMT 4.037421
TND 3.382578
TRY 54.903043
TTD 7.808341
TWD 37.208296
TZS 3062.670117
UAH 51.640496
UGX 4295.886455
USD 1.153549
UYU 46.446538
UZS 13744.098214
VES 870.019586
VND 30263.356394
VUV 137.669465
WST 3.148285
XAF 655.481924
XAG 0.018702
XAU 0.00027
XCD 3.117524
XCG 2.078512
XDR 0.814275
XOF 655.484763
XPF 119.331742
YER 273.24689
ZAR 18.82232
ZMK 10383.327655
ZMW 21.941003
ZWL 371.442287
  • NGG

    -0.1600

    80.26

    -0.2%

  • GSK

    -0.0700

    51.46

    -0.14%

  • RYCEF

    0.6000

    21

    +2.86%

  • CMSC

    -0.0600

    21.73

    -0.28%

  • RIO

    -0.5400

    100.97

    -0.53%

  • AZN

    -0.4620

    161.038

    -0.29%

  • BTI

    -0.7200

    58.55

    -1.23%

  • RELX

    -1.3150

    35.295

    -3.73%

  • VOD

    0.6800

    15.99

    +4.25%

  • BCC

    -1.4500

    83.35

    -1.74%

  • CMSD

    0.0200

    22.04

    +0.09%

  • BP

    0.3250

    41.535

    +0.78%

  • JRI

    0.0500

    12.72

    +0.39%

  • BCE

    0.4280

    22.488

    +1.9%

  • RBGPF

    0.0000

    69.74

    0%

Ketamine pill treats depression without psychedelic effects: study
Ketamine pill treats depression without psychedelic effects: study / Photo: Ed JONES - AFP/File

Ketamine pill treats depression without psychedelic effects: study

A new pill that slowly releases ketamine could treat people with severe depression without giving them the psychedelic side effects of the often-misused drug, early trial results suggested on Monday.

Text size:

First developed in the 1960s as an anaesthetic, ketamine's hallucinogenic and dissociative effects led to it becoming a party drug dubbed "Special K".

However, mounting research has demonstrated that ketamine is effective for the roughly quarter of people suffering from depression who see little benefit from common anti-depressant drugs.

In many countries, ketamine has been prescribed for depression for years.

US billionaire Elon Musk told CNN in March that he regularly uses a small amount of prescribed ketamine because it is "helpful for getting one out of the negative frame of mind".

The drug has long been administered intravenously in clinics, but more recently a nasal spray using a derivative called esketamine has increased in popularity.

Both can cause patients to have side effects such as dissociation, high blood pressure and an elevated heart rate.

There are also fears that medical use of the drug could slide into abuse.

The pill described in the journal Nature Medicine on Monday takes more than 10 hours to break down in the liver, lead study author Paul Glue told AFP.

"The really interesting feedback from patients is the lack of side effects -- no euphoria, no dissociation," said the researcher at New Zealand's University of Otago.

"I don't think these tablets would appeal to people who are abusing ketamine."

- Electro-shock alternative -

The phase 2 trial involved more than 270 people with depression who had previously tried an average of four different anti-depressant drugs.

More than half taking the ketamine pill went into remission for their depression, while 70 percent of the placebo group relapsed after 13 weeks, the study said.

Julaine Allan, an expert on mental health and addiction at Australia's Charles Sturt University who was not involved in the study, praised the trial while emphasising that more research is needed.

Ketamine does not work for everyone, and the "positive effects may wear off over time," she told AFP.

Michel Hoffmann, a psychiatrist at Geneva University Hospitals, said there is "real enthusiasm" in the medical community for ketamine's potential for treating depression.

"For patients who don't respond to conventional drugs, ketamine offers a way to avoid electro-shock therapy," he told AFP.

This last-resort treatment, which involves sending electric currents through the brain, has been proven to be effective.

But it can cause memory loss -- and some patients fear the procedure after seeing depictions of it in films such as "One Flew Over the Cuckoo's Nest".

- Fears of 'opioid style crisis' -

Some psychiatrists remain hesitant to prescribe ketamine for depression, fearing their patients could end up misusing the drug.

Last year, "Friends" actor Matthew Perry became the latest high-profile death from a ketamine overdose.

US police are investigating how Perry obtained the doses that caused his death -- he had reportedly not had a supervised infusion session for several days.

One potential benefit of quick-acting ketamine seen in previous research is that it could help patients considering suicide.

But there is "the plausible concern that the widespread use of ketamine might trigger a new opioid style crisis," Oxford researcher Riccardo De Giorgi said in a 2022 BMJ editorial.

By ridding ketamine of the side effects sought by some partygoers, the slow-release pill could alleviate some of these concerns.

There were still some side effects from the pill, the most common being headaches, dizziness and anxiety.

More research including phase 3 trials is needed before the drug can be reviewed by national medicine agencies, meaning it will be at least two or three years before patients could potentially access the pills, Glue said.

(S.G.Stein--BBZ)